DRG Market Assessment 보고서

Dyslipidemia is a key modifiable risk factor for cardiovascular (CV) disease. Current lipid-modifying therapies, including statins, ezetimibe, fibrates,omega-3 fatty acid compounds, and PCSK9…

Metformin is the most heavily prescribed type 2 diabetes (T2D) drug and dominates the early lines of therapy before disease progression requires insulin replacement. The emergence of more-effective…

The age-related macular degeneration (AMD) market in the United States is unique given that market penetration of approved branded therapies—Roche / Genentech’s Lucentis, Regeneron’s Eylea,…

Non-Hodgkin’s lymphoma (NHL) and chronic lymphocytic leukemia (CLL) encompass a heterogeneous group of hematological malignancies that can be broadly classified into indolent and aggressive…

Clarivate Epidemiology’s coverage of sarcoidosis comprises epidemiological estimates of key patient populations in the major mature pharmaceutical markets (the United States, France, Germany,…

KEY BENEFITS AND USES Pinpoint current drug positioning and uptake in one snapshot to facilitate forecasting. Drill down into physicians’ treatment sequences and understand whom to…

Established targeted therapies, such as Janssen’s interleukin (IL)-12/23 inhibitor Stelara, AbbVie’s tumor necrosis factor-alpha (TNF-α) inhibitor Humira, and Novartis’s IL-17A inhibitor…

Key benefits and uses Pinpoint current drug positioning and uptake in one snapshot to facilitate forecasting. Drill down into physicians’ treatment sequences and understand who to position…

The regulatory and market access landscape for biosimilars is constantly evolving. For a company seeking to develop a biosimilar for multiple markets, keeping track of the similarities and…

Renal anemia is a common complication of chronic kidney disease (CKD). The primary goal of treatment of renal anemia is to increase and maintain Hb levels and reduce the risk of complications of…

Clarivate Epidemiology’s coverage of alzheimer’s disease comprises epidemiological estimates of key patient populations across 45 countries worldwide. We report the diagnosed events of alzheimer’s…

Clarivate’s Extrapolated Worldwide Coverage is the first and only evidence-based data set of epidemiological forecasts for key AD patient populations, covering 171 countries and more than 99% of…